Enlivex Therapeutics (ENLV)
(Real Time Quote from BATS)
$1.36 USD
+0.01 (0.37%)
Updated Jul 22, 2024 02:56 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ENLV 1.36 +0.01(0.37%)
Will ENLV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ENLV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENLV
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
New Strong Buy Stocks for November 3rd
ENLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for October 27th
New Strong Buy Stocks for October 19th
Other News for ENLV
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Enlivex Commences Key Trial for Thumb Osteoarthritis
Enlivex Therapeutics doses first patient in Phase I/II trial of Allocetra
Enlivex Webinar to Discuss Breakthrough Immunotherapy